PYC pyc therapeutics limited

A Star in the Making, page-17

  1. 1,553 Posts.
    lightbulb Created with Sketch. 2333
    We now know from the announcement of 19 June 2017, that Dr Robert Hayes, formerly the Head of Centyrex and VP of Janssen, was instrumental in the progression of the Janssen collaboration to use phylomers for the intracellular delivery of a designated payload. Back in late 2013, however, the detail around the collaboration was the subject of fierce speculation which has subsequently turned out to be well informed.

    BEN_1312, a virulence factor in cell invasion, was favoured by a number of posters as the phylomer most likely. It appears the past has caught up with the present due to the Benefactor.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$1.27
Change
0.005(0.40%)
Mkt cap ! $740.7M
Open High Low Value Volume
$1.27 $1.29 $1.27 $406.0K 319.3K

Buyers (Bids)

No. Vol. Price($)
1 13987 $1.27
 

Sellers (Offers)

Price($) Vol. No.
$1.29 1380 1
View Market Depth
Last trade - 16.10pm 27/06/2025 (20 minute delay) ?
PYC (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.